-
CDK Related Products (488)
Related Products (488)
-
AS2863619 (GMP)
0 ImagesCat. No.: HY-126675GCAS No.: 2241300-51-4AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4+ T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects.
-
rel-(2S,3R)-Voruciclib hydrochloride
0 ImagesCat. No.: HY-12422ECAS No.: 1253647-46-9rel-(2S,3R)-Voruciclib hydrochloride is the rel-(2S,3R)-enantiomer of Voruciclib. Voruciclib is an orally active CDK inhibitor.
-
CDK/HDAC-IN-4
0 ImagesCat. No.: HY-169075CDK/HDAC-IN-4 is a high selective dual cyclin-dependent kinase (CDK)/histone deacetylase (HDAC) inhibitor with IC50 values of 88.4 and 168.9 nM, respectively. CDK/HDAC-IN-4 exhibits antiproliferative capacities against hematological and solid tumor cells. CDK/HDAC-IN-4 also induces MV-4-11 cell Apoptosis and S cell cycle arrests. CDK/HDAC-IN-4 possesses a significant antitumor potency in the MV-4-11 xenograft model.
-
Anticancer agent 299
0 ImagesCat. No.: HY-181130CAS No.: 1414873-26-9Anticancer agent 299 (compound P12) is a cell-cycle inhibitor, senescence inducer, apoptosis inducer, and antiproliferative agent. Anticancer agent 299 exhibits selective activity against cancer cells with minimal effects on non-tumoral chondrocyte cells at relevant concentrations. Anticancer agent 299 can be used for the research of ER+/HER2− breast cancer and BRAF-mutant melanoma.
-
Cdc7-IN-8
0 ImagesCat. No.: HY-143377CAS No.: 2606780-38-3Cdc7-IN-8 is a potent inhibitor of Cdc7. Cdc7 is a serine/threonine kinase which activates MCM promotion by phosphorylating the microchromosome maintenance protein (MCM protein), an important element of the DNA replication initiator. Cdc7-IN-8 has the potential for the research of cancer diseases (extracted from patent WO2021032170A1, compound 1-1/1-2).
-
CDK2/FLT4/PDGFRA-IN-1
0 ImagesCat. No.: HY-173124CDK2/FLT4/PDGFRA-IN-1 (Compound 4a) is a potent inhibitor of CDK2/cyclin A, FLT4 (VEGFR3) and PDGFRA, with IC50s of 1.672, 0.554, and 0.629 μM, respectively. CDK2/FLT4/PDGFRA-IN-1 exhibits potent antiproliferative effects against cancer cells (lung EBC-1, pancreatic ductal adenocarcinoma AsPC-1, colorectal HT-29 cells). CDK2/FLT4/PDGFRA-IN-1 can also induce apoptosis in cancer cells.
-
CDK-IN-20
0 ImagesCat. No.: HY-184320CAS No.: 2776187-63-2
-
BAY-958
0 ImagesCat. No.: HY-121081CAS No.: 1335490-39-5BAY-958 is a potent PTEFb/CDK9 inhibitor with high selectivity demonstrated, particularly within the CDK family. BAY-958 shows strong antiproliferative activity against cancer cell lines such as HeLa and MOLM-13. BAY-958 exhibits good metabolic stability. BAY-958 effectively inhibits tumor growth in mouse xenograft models without significant toxicity.
-
CDK7-IN-26
0 ImagesCat. No.: HY-157210CAS No.: 3024545-79-4
-
CDK2/CycA1 Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70669CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycA1 Recombinant Human Active Protein Kinase is an ortholog of CDK2.
-
CDK9-IN-25
0 ImagesCat. No.: HY-155843CDK9-IN-25 (compound 4a) is an imidazopyrazine CDK9 inhibitor (IC50: 0.24 μM). CDK9-IN-25 has good affinity to the main protease of COVID-19 and has antiviral activity against human coronavirus 229E (IC50: 63.28 μM).
-
CDK3/CycO Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70680CDK3 is a major player driving retinoblastoma (Rb) phosphorylation during the G0/G1 transition and in the early G1 phase of the cell cycle. CDK3 interacts with various transcription factors involved in cell proliferation, differentiation, and transformation driven by the EGFR/Ras signaling pathway. CDK3/CycO Recombinant Human Active Protein Kinase is an ortholog of CDK3.
-
Cdc7-IN-21
0 ImagesCat. No.: HY-117677CAS No.: 1330781-04-8Cdc7-IN-21 (compound 10c) is a potent and selective Cdc7 inhibitor with an IC50 of 0.07 nM. Cdc7-IN-21 can be used to study cancer.
-
CDK9-IN-26
0 ImagesCat. No.: HY-155844CDK9-IN-26 (compound 1is a CDK9 inhibitor (IC50=0.18 μM). .
-
ALK/PI3K/AKT-IN-1
0 ImagesCat. No.: HY-173007CAS No.: 3050831-84-7ALK/PI3K/AKT-IN-1 (Compound 45) inhibits the proliferation of cancer cell A549, H1975 and PC9 with an IC50 of 0.44, 0.83 and 1.51 μM. ALK/PI3K/AKT-IN-1 increases the expression of p21 and p27, inhibits the activity of CDK2 and p-Rb, arrests the cell cycle at G1 phase. ALK/PI3K/AKT-IN-1 inhibits the ALK/PI3K/AKT signaling pathway, promotes the depolarization of mitochondrial membrane potential, and inducing apoptosis in A549 cell. ALK/PI3K/AKT-IN-1 inhibits the formation and growth of A549 cell spheroids.
